Optimus Announces Interim Clinical Results from Phase III Clinical Trials of Molnupiravir Conducted in India

Hyderabad (Telangana) [India], July 21: Optimus Pharma on Sunday submitted the interim result of Phase III Clinical Trials for orally administered Molnupiravir capsules on patients with Mild Covid-19 patients. With an acute shortage of antiviral drugs in the market against the SARS-CoV-2 infection, it is imperative that more drugs with potent antiviral activity against SARS-CoV-2 be introduced.

In a statement, the MD and Chairman Dr. D Srinivasa Reddy had declared that Optimus pharma has internally developed the active pharmaceutical ingredient (API) and the formulations for the product and had obtained approval for conducting Phase 3 Clinical Trial.

As per the clinical trial protocol approved, 1218 subjects with mild COVID-19 will be randomised in the study in a 1:1 ratio to Molnupiravir with the standard of care, or standard of care alone. The treatment duration is a maximum of 05 days and the total study duration will be a maximum of 28 days from randomisation.

“Optimus is all geared to immediately begin manufacturing of Molnupiravir for COVID-19 patients in India. The interim results on 353 patients have shown promising results of Molnupiravir. The drug has been successful in reducing viral load effectively with RT-PCR negativity achieved 78.3 % in the test arm compared to 48.4% in the standard of care arm on Day 5. Day 10 and Day 14 of the treatment duration have also given excellent results wherein the remaining patients have successfully achieved RT-PCR negativity. The trial has also revealed clinical improvement in a significantly high proportion of patient’s health. The safety of the drug has also been established with no observed side effects, co-morbidity, or morbidity observed during and after the treatment duration,” Chairman & Managing Director – Dr. D Srinivasa Reddy said.

Optimus has approached the Drugs Controller General of India (DCGI) to seek Emergency Use Authorization for Molnupiravir in India.

Optimus Pharma is committed to serve the nation and fight back the pandemic to restore normalcy in the lives of people affected by COVID-19 at the earliest. With the cooperation of the government and our stakeholders, and a special thanks to the Subject Expert Committee of the CDSCO for their valuable contribution and their recommendations to the project, we hope to deliver the product in India by leveraging our solid distribution strength across the country.

Leave a Reply

Your email address will not be published. Required fields are marked *

National

Leading Media Firm, Pooja Movie Creation Offers WFH Opportunities To Thousands Of Unemployed Youth

New Delhi (India), January 20: Despite the growing threats of COVID19, unemployment is increasing throughout the country as a result of the lockdown; millions of people have lost their jobs in the previous two years, and COVID19 is spreading rapidly across the country again in the third wave. The employment crisis has resurfaced in front […]

Read More
National

Dr. Dinesh Sabnis of India is Conferred with Honorary Decree of Colonel by the Governor of Commonwealth of Kentucky-USA

January 20: Dr. Dinesh Sabnis is Ex. Ranji Player (National Level) & Sports Mentor; he has been working in the Education Industry for the last 15 years as a Senior Educationist and Administrator. He is also involved in Humanitarian projects for various International NGOs for past six years, which are on the roster of United […]

Read More
National

Mohit Kamboj Bharatiya, I Stand with The Truth and The Truth Always Stands Above All

January 20:Truth is a powerful thing, and it takes courage to stand by the truth in a world full of lies. Not just that, standing up for what you believe in is also easier said than done, many people cave under pressure put on them by society to believe what the masses believe in. Everyone […]

Read More